PRODUCT DETAILS
Wegovy (Retatrutide) is a developing triple hormone receptor agonist (GIP, GLP-1, and glucagon receptors) that is now being tested in clinical studies to treat obesity, type 2 diabetes, and metabolic disorders.
It is regarded as a next-generation weight loss medicine, perhaps more successful than both semaglutide and tirzepatide.
• Works by activating three metabolic hormone receptors:
◦ GLP-1: improves insulin release, reduces appetite.
◦ GIP: enhances insulin sensitivity, supports energy balance.
◦ Glucagon: increases energy expenditure and promotes fat burning.
This threefold action gives Retatrutide a potent metabolic effect on weight loss, blood sugar levels, and overall energy balance.
BENEFITS OF Wegovy:
Extreme Weight Loss
• Up to 24% body weight reduction in trials (even higher than tirzepatide).
• Some participants lost 60+ pounds over 48–72 weeks.
• Among the most effective weight loss drugs ever tested.
Improves Blood Sugar in Type 2 Diabetes
• Strong HbA1c reductions (1.8–2.2% or more).
• Supports glucose control across fasting and post-meal periods.
Increases Energy Expenditure
• Unlike semaglutide or tirzepatide, Retatrutide’s glucagon activation helps burn more calories.
• Enhances fat oxidation and reduces fat storage.
Improves Liver Health
• Shown to reduce liver fat in patients with NAFLD/NASH.
• May slow or reverse early liver damage (inflammation/fibrosis).
Enhances Cardiometabolic Markers
Reduces:
◦ Triglycerides
◦ LDL cholesterol
◦ Blood pressure
◦ Inflammatory markers
• Improves insulin sensitivity.
Preserves Muscle Mass
• Similar to tirzepatide, early trials suggest lean mass retention during weight loss.
• Supports healthier body composition (fat loss > muscle loss).
Suppresses Appetite
• Stronger appetite suppression than GLP-1 or GLP-1/GIP drugs alone.
• Enhances satiety, reduces cravings and emotional eating.
Improves Quality of Life
Participants reported:
◦ Better energy
◦ Greater mobility
◦ Fewer obesity-related symptoms
◦ Better mental and emotional health
